Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB002 recombinant peptide inhalation solution for adult hospital-acquired pneumonia (Phase II, randomized, double-blind)
CTR20263285Phase 2Active
- Sponsor
- Nanning Jirui Biopharmaceutical
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of seralutinib in hospital-acquired pneumonia (HAP), sponsored by Nanning Jirui Biopharmaceutical. Started Aug 2026; status: active.
02
Drugs
seralutinib
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on CTR20263285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263285.